
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Wnt-2 CRISPR Activation Plasmid (h) | sc-402665-ACT | 20 µg | $397.00 | |||
Wnt-2 CRISPR Activation Plasmid (h2) | sc-402665-ACT-2 | 20 µg | $397.00 |
Human WNT2 encodes Wnt-2, a secreted glycoprotein ligand that activates Wnt signaling to regulate embryonic development, tissue patterning, and adult stromal–epithelial communication. Wnt-2 primarily engages Frizzled receptors and LRP5/6 co-receptors to promote β-catenin stabilization and transcriptional programs controlling proliferation, differentiation, and cell fate decisions. It also interfaces with non-canonical Wnt pathways that influence cytoskeletal dynamics and migration in a context-dependent manner. Dysregulated WNT2 expression and pathway activity have been associated with altered morphogenesis and microenvironmental signaling changes relevant to oncogenic processes and fibrotic remodeling, supporting its study as a pathway node in disease-relevant models.
Wnt-2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous WNT2 expression without altering the underlying DNA sequence.
Wnt-2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the WNT2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the WNT2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Wnt-2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native WNT2 locus and enabling the study of Wnt-2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Wnt-2 pathway restoration in tumor cells with silenced or reduced WNT2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.